B型主动脉夹层TEVAR时机与主动脉重塑及临床结局的关系
该多中心回顾性研究纳入87例B型主动脉夹层患者,按TEVAR时机分为急性/亚急性(≤6周,n=35)、早期慢性(6周至1年,n=20)和晚期慢性(>1年,n=32)三组。结果显示急性/亚急性与早期慢性组主动脉重塑及临床结局相似且优于晚期慢性组,提示症状发作后1年可作为TEVAR实现最佳重塑与安全性的时间上限。
要点
- 急性/亚急性与早期慢性期TEVAR的主动脉重塑和临床结局相似,均优于晚期慢性期。
- 晚期慢性组5年无主要不良主动脉事件生存率最低(73.1%)。
- 症状发作后1年可能是TEVAR实现最佳主动脉重塑与安全性的时间上限。
核心结论
- B型主动脉夹层在急性/亚急性期和早期慢性期行TEVAR可获得相似的主动脉重塑和临床结局,且优于晚期慢性期TEVAR。
- 症状发作后1年可能是TEVAR实现最佳主动脉重塑和安全性的时间上限。
研究设计与样本
- 多中心回顾性分析,纳入2个中心共87例接受TEVAR的B型主动脉夹层患者。
- 按TEVAR时机分为急性/亚急性(≤6周,n=35)、早期慢性(6周至1年,n=20)和晚期慢性(>1年,n=32)三组。
- 评估系列CT血管造影上的主动脉尺寸变化和临床结局。
主要发现
- 急性/亚急性组TEVAR最常见指征为夹层并发症,而早期和晚期慢性组主要因主动脉扩张。
- 急性/亚急性组最大主动脉总直径小于早期和晚期慢性组(46.6±10.6 vs. 54.8±9.8 vs. 56.7±10.1 mm,P<0.001)。
- 急性/亚急性组假腔直径小于早期和晚期慢性组(30.9±11.0 vs. 35.2±12.0 vs. 39.9±13.4 mm,P=0.013)。
- 1年随访时,急性/亚急性组和早期慢性组最大主动脉总直径减小,晚期慢性组增大(-4.3±9.3 vs. -5.2±6.9 vs. 2.5±4.6 mm,P<0.001)。
- TEVAR后5年无主要不良主动脉事件(死亡、主动脉破裂或再干预)生存率在晚期慢性组最低(92.6% vs. 88.2% vs. 73.1%,P=0.033),急性/亚急性组与早期慢性组间无显著差异(P=0.680)。
临床怎么用
- 对于B型主动脉夹层,在急性/亚急性期或早期慢性期(症状发作后1年内)行TEVAR可能获得更优的主动脉重塑和临床结局。
- 晚期慢性期(>1年)行TEVAR需权衡主动脉重塑较差和主要不良主动脉事件风险较高的可能。
局限性
- 回顾性分析,样本量有限(共87例),可能存在选择偏倚。
- 仅纳入2个中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of the study was to investigate aortic remodeling and clinical outcomes after thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (AD) according to timing of the procedure. METHODS: A total of 87 patients with type B AD who underwent TEVAR at 2 centers were included in this retrospective analysis. Patients were divided into acute/subacute (≤6 weeks, n = 35), early chronic (6 weeks to 1 year, n = 20), and late chronic (>1 year, n = 32) groups according to the timing of TEVAR after symptom onset. Changes in aorta dimensions on serial computed tomography angiograms and clinical outcomes were evaluated. RESULTS: AD complications were the most common indication for TEVAR in the acute/subacute group, whereas aortic expansion was the main reason in the early and late chronic groups. Maximum total aorta diameter (46.6 ± 10.6 vs. 54.8 ± 9.8 vs. 56.7 ± 10.1 mm, P < 0.001) and false lumen diameter (30.9 ± 11.0 vs. 35.2 ± 12.0 vs. 39.9 ± 13.4 mm, P = 0.013) were smaller in the acute/subacute group than in the early and late chronic groups. At 1-year follow-up, maximum total aorta diameter was decreased in the acute/subacute and early chronic groups and increased in the late chronic group (-4.3 ± 9.3 vs. -5.2 ± 6.9 vs. 2.5 ± 4.6 mm, P < 0.001). Survival free from the major adverse aortic event (death, aortic rupture, or reintervention) at 5 years after TEVAR was lowest in the late chronic group (92.6% vs. 88.2% vs. 73.1%, P = 0.033) but not significantly different between the acute/subacute and early chronic groups (P = 0.680). CONCLUSIONS: TEVAR in the acute/subacute and early chronic phases of type B AD resulted in similar aortic remodeling and clinical outcomes, which were more favorable than those with TEVAR performed during late chronic AD. This finding suggests 1 year after the onset of type B AD symptoms as the upper time threshold for TEVAR to achieve optimal aortic remodeling and safety.
引用
- Lee SJ, Kang WC, Ko YG, et al. Aortic Remodeling and Clinical Outcomes in Type B Aortic Dissection According to the Timing of Thoracic Endovascular Aortic Repair. Ann Vasc Surg. 2020. PMID: 32234394. doi:10.1016/j.avsg.2020.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。